Colorectal Cancer Epidemiology Analysis and Forecast, 2021-2031

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Colorectal Cancer Epidemiology Analysis Report Overview

The total number of cases affected by colorectal cancer was 3,183,569 in 2021. The number of cases is expected to grow at an AGR of more than 3% during the forecast period. Colorectal cancer, also referred as bowel cancer, is the cancer of the colon, rectum, or rectosigmoid junction. It is a type of gastrointestinal malignancy originating from either the colon or the rectum. Although both forms can be defined as colon or rectal cancers, depending on their origin, they are often merged because of the many biologically and clinically common features (American Cancer Society, 2020a). CRC is the second most lethal cancer after lung cancer, and the third most diagnosed malignant tumor worldwide.

Colorectal Cancer Market Outlook

Colorectal Cancer Market Outlook

For more insights on colorectal cancer market forecast data, download a free report sample

The Colorectal Cancer Epidemiology Analysis and Forecast market research report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CRC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). The report includes a 10-year epidemiology forecast for the diagnosed incident cases of CRC. The diagnosed incident cases of CRC are segmented by age (18–29 years, 30–39 years, 40–49 years, 50–59 years, 60–69 years, 70–79 years, and 80 years and older) and sex.

Total Colorectal Cancer Cases (2021) 3,183,569
Growth Rate (AGR) >2% (2021-2031)
Key Age Segments 18-29 years, 30-39 years, 40-49 ears, 50-59 years, 60-69 years, 70-79 years, >80 years
Key Stages Stage I, Stage II, Stage III, and Stage IV

What are the market dynamics in the colorectal cancer market?

Although research studies have found several factors that can increase the risk of CRC, exactly how all those factors might cause this cancer remains unclear. A combination of genetic and environmental factors is most likely responsible for CRC. According to research in 2022, around a significant percentage of CRC cases develop for no clear reason, while a small percent seem to result from inherited syndromes, and a significant percent happen in family clusters. Among the non-modifiable risk factors of CRC are older age; male sex; being of African or Ashkenazi Jewish descent; family or personal history of CRC, polyps, or inflammatory bowel disease (IBD); and having an inherited syndrome due to gene mutations such as Lynch syndrome, also referred as hereditary non-polyposis CRC (HNPCC), and familial adenomatous polyposis. Many lifestyle-related modifiable factors are associated to CRC. Being overweight or obese, physical inactivity, eating a low-fiber and high-fat diet with red and processed meat regularly, sugary drinks, smoking, and alcohol are all linked to CRC (American Cancer Society, 2020b). In fact, the links between diet, exercise, and weight and CRC risk are some of the strongest for any type of cancer. In addition, type 2 diabetes, hypertension, chronic obstructive pulmonary disease (COPD), and congestive heart failure (CHF) are common comorbidities in CRC patients.

What are the key age segments in the colorectal cancer market?

The key age segments in the colorectal cancer market are 18-29 years, 30-39 years, 40-49 ears, 50-59 years, 60-69 years, 70-79 years, >80 years. In 2021, for the 8MM combined, adults ages 70–79 years contributed the highest proportion of the diagnosed incident cases of CRC.

Colorectal cancer market, by age group

Colorectal cancer market, by age group

For more age group insights, download a free report sample

What are the key stages in the colorectal cancer market?

The key stages in the colorectal cancer market are stage I, stage II, stage III, and stage IV. In the 8MM, the highest number of diagnosed incident cases of CRC was in stage II, followed by stage III and stage I.

Colorectal cancer market, by stages

Colorectal cancer market, by stages

For more stage insights, download a free report sample

Scope

  • The Colorectal Cancer (CRC) Epidemiology Report and Model provide an overview of the risk factors and global trends of CRC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China).
  • The report includes a 10-year epidemiology forecast for the diagnosed incident cases of CRC. The diagnosed incident cases of CRC are segmented by age (18–29 years, 30–39 years, 40–49 years, 50–59 years, 60–69 years, 70–79 years, and 80 years and older) and sex. The diagnosed incident cases are further segmented by the American Joint Committee on Cancer (AJCC) stage at diagnosis (stage I, stage II, stage III, and stage IV), by recurrence of stages I–III into stage IV disease, and by molecular markers. The report also provides a 10-year epidemiological forecast of the five-year diagnosed prevalent cases of CRC.
  • The CRC epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

  • The Colorectal Cancer Epidemiology series will allow you to:
  • Develop business strategies by understanding the trends shaping and driving the global CRC market.
  • Quantify patient populations in the global CRC market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CRC therapeutics in each of the markets covered.
  • Understand magnitude of CRC population by stage at diagnosis, recurrence of stages I–III into stage IV disease, and molecular markers.

Table of Contents

1 Colorectal Cancer: Executive Summary

1.1 Catalyst

1.2 Related Reports

1.3 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 8MM Forecast Methodology

2.4.1 Sources

2.4.2 Forecast Assumptions and Methods

2.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of CRC

2.4.4 Forecast Assumptions and Methods: Diagnosed Incident Cases of CRC by AJCC Stage at Diagnosis

2.4.5 Forecast Assumptions and Methods: Diagnosed Incident Cases of CRC by Recurrence of Stages I–III into Stage IV Disease

2.4.6 Forecast Assumptions and Methods: Diagnosed Incident Cases of CRC by Molecular Markers

2.4.7 Forecast Assumptions and Methods: Five-Year Diagnosed Prevalent Cases of CRC

2.5 Epidemiological Forecast for CRC (2021–31)

2.5.1 Diagnosed Incident Cases of CRC

2.5.2 Age-Specific Diagnosed Incident Cases of CRC

2.5.3 Sex-Specific Diagnosed Incident Cases of CRC

2.5.4 Diagnosed Incident Cases of CRC by AJCC Stage at Diagnosis

2.5.5 Diagnosed Incident Cases of CRC by Recurrence of Stages I–III into Stage IV Disease

2.5.6 Diagnosed Incident Cases of CRC by Molecular Markers

2.5.7 Five-Year Diagnosed Prevalent Cases of CRC

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 COVID-19 Impact

2.6.3 Limitations of the Analysis

2.6.4 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologist

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.2.4 Global Head and EVP of Healthcare Operations and Strategy

 Contact Us

Table

Table 1: Summary of Newly Added Data Types

Table 2: Summary of Updated Data Types

Table 3: Risk Factors and Comorbid Conditions Associated with CRC

Table 4: 8MM, Diagnosed Incident Cases of CRC by Molecular Markers, Both Sexes, Ages ≥18 Years, N, 2021

Figures

Figure 1: 8MM, Diagnosed Incident Cases of CRC, Both Sexes, N, Ages ≥18 Years, 2021 and 2031

Figure 2: 8MM, Five-Year Diagnosed Prevalent Cases of CRC, Both Sexes, N, Ages ≥18 Years, 2021 and 2031

Figure 3: 8MM, Diagnosed Incidence of CRC, Men, Cases Per 100,000 Population, Ages ≥18 Years, 2011–31

Figure 4: 8MM, Diagnosed Incidence of CRC, Women, Cases Per 100,000 Population, Ages ≥18 Years, 2011–31

Figure 5: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of CRC

Figure 6: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Stage at Diagnosis

Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Recurrence into Stage IV Disease

Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Molecular Markers (KRAS Mutation, NRAS Mutation, BRAF Mutation, BRAF V600E Mutation, and PIK3CA/PTEN Mutation)

Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Molecular Markers (MSI-H/dMMR Molecular Subtype, HER2 Amplification, MET Amplification, and NTRK Gene Fusion)

Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Molecular Markers (DPYD, High TMB, Elevated CEA, and UGT1A1 Mutation)

Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Molecular Markers (POLE Mutation, TP53 Mutation, APC Mutation, and PD-L1 Expression on Tumors)

Figure 12: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of CRC

Figure 13: 8MM, Diagnosed Incident Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2021

Figure 14: 8MM, Diagnosed Incident Cases of CRC by Age, N, Both Sexes, 2021

Figure 15: 8MM, Diagnosed Incident Cases of CRC by Sex, N, All Ages, 2021

Figure 16: 8MM, Diagnosed Incident Cases of CRC by AJCC Stage at Diagnosis, N, All Ages, 2021

Figure 17: 8MM, Diagnosed Incident Cases of CRC by Recurrence of Stages I–III into Stage IV Disease, N, Both Sexes, Ages ≥18 Years, 2021

Figure 18: 8MM, Five-Year Diagnosed Prevalent Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2021

Frequently asked questions

Colorectal Cancer Epidemiology Analysis and Forecast, 2021-2031 thematic reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Colorectal Cancer Epidemiology Analysis and Forecast, 2021-2031 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Colorectal Cancer Epidemiology Analysis and Forecast, 2021-2031 in real time.

  • Access a live Colorectal Cancer Epidemiology Analysis and Forecast, 2021-2031 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.